Table 2.
Clinical characteristics of the participants in the HAART, HAART with protease inhibitor (PI), and HAART with nonnucleoside reverse-transcriptase inhibitor (NNRTI) analyses at follow-up.
| Variable | HAARTa | HAART with PIb |
HAART with NNRTIc |
|---|---|---|---|
| Duration of follow-up, median years (interquartile range) | 3 (1–7) | 2 (1–6) | 1 (0–3) |
| No. of patients with HAART initiation | 610 | 543 | 223 |
| Cumulative exposure, median years (IQR) | 3 (1–7) | 3 (1–7) | 2 (1–5) |
| No. (%) of patients remaining in follow-up through 30 June 2006d | 330 (27) | 263 (21) | 155 (12) |
| No. (%) of patients censored at first follow-up with missing CD4+ cell percentage datad | 906 (73) | 851 (69) | 614 (50) |
| No. (%) of patients censored because of switching regimend | … | 122 (10) | 467 (30) |
a
The HAART group (n = 610) includes HAART with only PI (n = 387), HAART with only NNRTI (n = 67), and HAART with both PI and NNRTI (n = 156).
b
The HAART with PI group (n = 543) includes HAART with only PI (n = 387) and HAART with both PI and NNRTI (n = 156).
c
The HAART with NNRTI group (n = 223) includes HAART with only NNRTI (n = 67) and HAART with both PI and NNRTI (n = 156).
d
n = 1236.